SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

Rigel Pharmaceuticals, Inc. (RIGL) News

Follow Rigel Pharmaceuticals, Inc. (RIGL) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 11 public stories across 7 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol RIGL Asset equity Sector Markets 90 days 8 Last 40.05 Updated Nov 07, 2026, 08:06 AM UTC Open live news feed Open RIGL chart & news
M Rigel Posts $80.9M in Q3 Revenue EQUITY | Nov 07, 2026, 08:06 AM UTC M Rigel Pharmaceuticals Reports Quarterly Results Rigel Pharmaceuticals reported results for the quarter ended September 30. The supplied text contains no financial figures. EQUITY | Nov 05, 2026, 10:04 PM UTC M Rigel Pharmaceuticals Q3 2026 Earnings Call Begins Rigel Pharmaceuticals' quarterly earnings call has begun. EQUITY | Nov 05, 2026, 09:27 PM UTC L Rigel Pharmaceuticals 3Q 2026: Revenue $80.89M, EPS $0.65 — 10-Q Summary Rigel’s third-quarter revenue rose 16% year over year, while net income declined as higher research and development and selling, general and administrative expenses outweighed revenue growth. Sales of REZLIDHIA and newly EARNINGS | Nov 05, 2026, 09:13 PM UTC H RIGL: VEPPANU launch and robust pipeline drive growth, with strong financials and raised guidance A four-part growth strategy is driving expansion, highlighted by the VEPPANU acquisition and launch, which targets a billion-dollar breast cancer market. The pipeline, led by R289 in MDS, shows promising clinical results EARNINGS | Sep 15, 2026, 03:00 PM UTC L RIGL: VEPPANU launch and robust pipeline position the business for accelerated growth and profitability A four-pillar growth strategy is driving commercial expansion, highlighted by the VEPPANU acquisition and launch, which is expected to be a major growth driver in metastatic breast cancer. The pipeline, especially R289 i MNA | Sep 15, 2026, 02:40 PM UTC L RIGL: VEPPANU's launch and pipeline progress drive growth, with strong financials and global expansion The conference highlighted accelerated commercial growth, with VEPPANU's U.S. launch and global expansion, strong Q2 2026 financials, and a robust pipeline led by R289 in lower-risk MDS. Strategic licensing and disciplin NEWS | Sep 15, 2026, 02:06 PM UTC L RIGL - Rigel to Participate in Upcoming September Investor Conferences RIGL - Rigel to Participate in Upcoming September Investor Conferences EQUITY | Sep 02, 2026, 12:05 PM UTC L Rigel PT raised to $49 from $40 by Piper Sandler Piper Sandler raised its price target on Rigel (RIGL) to $49 from $40, according to TradeXchange Newsdesk. EQUITY | Aug 17, 2026, 11:28 AM UTC L Rigel announces VEPPANU availability for ER+/HER2- ESR1-mutated breast cancer Rigel (RIGL) says VEPPANU™ (vepdegestrant) is now available for patients with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer. EQUITY | Aug 13, 2026, 12:06 PM UTC L RIGL RIGL - Rigel Reports Second Quarter 2026 Financial Results RIGL RIGL - Rigel Reports Second Quarter 2026 Financial Results EARNINGS | Aug 04, 2026, 08:01 PM UTC